Black Diamond Therapeutics, Inc. - SIC # 2830 -

Ticker Exchange SIC # Website Latest Ticker
BDTX Nasdaq 2830 www.blackdiamondtherapeutics.com

Select one of the four (4) financial statement analysis reports below to view the ratio analysis report for your selected company:

Financial Analysis - Public Company vs Industry Ratio Analysis
Financial Analysis - Public Company
Industry Ratios Analysis
Public Company vs Public Company

Latest Headlines for Black Diamond Therapeutics, Inc.

Black Diamond Therapeutics Touts Silevertinib Lung Cancer Data, Eyes FDA Path - Jun 6th, 2026 3:04 am
BDTX Broadens EGFR Reach into Glioblastoma, Adding a Fresh Catalyst - May 27th, 2026 9:16 am
Black Diamond Stock Outlook After Q1 Beat and Cash Runway - May 27th, 2026 9:13 am
BDTX Silevertinib Data in EGFR NSCLC: What Investors Need to Know - May 27th, 2026 9:10 am
BDTX Stock Slumps on Mixed Phase II Frontline NSCLC Study Data - May 25th, 2026 8:53 am
Black Diamond Therapeutics to Participate in Jefferies Global Healthcare Conference - May 22nd, 2026 6:00 am
Black Diamond Therapeutics Lung Cancer Drug Shows 15.2-Month PFS in Phase 2 Study - May 21st, 2026 5:09 pm
Black Diamond Therapeutics Announces Positive Phase 2 Results for Silevertinib in Frontline NSCLC Patients with EGFR Non-Classical Mutations - May 21st, 2026 3:13 pm
Black Diamond Therapeutics to Host Webcast for Investors Highlighting Updated Results from Phase 2 Trial of Silevertinib in 1L EGFRm NSCLC - May 19th, 2026 6:00 am
BDTX Shares Gain 11% in a Week: Here's What You Should Know - May 11th, 2026 9:48 am
Black Diamond Therapeutics (NASDAQ:BDTX) Is In A Good Position To Deliver On Growth Plans - May 11th, 2026 5:54 am
Black Diamond Therapeutics Reports First Quarter 2026 Financial Results and Provides Corporate Update - May 7th, 2026 5:30 am
Implied Volatility Surging for Black Diamond Therapeutics Stock Options - Apr 28th, 2026 5:05 am
BDTX and the CNS-Active EGFR Trend: Why C797S Is the Prize - Apr 23rd, 2026 9:29 am
BDTX Stock: Neutral Zacks Rank, $4 Target, and What Must Go Right - Apr 23rd, 2026 9:26 am
Black Diamond's Lead Drug Silevertinib: Key Data, Catalysts, and Risks - Apr 23rd, 2026 9:23 am
Black Diamond Therapeutics Announces Oral Presentation of Silevertinib Phase 2 Data in Frontline EGFRm NSCLC Patients at the 2026 ASCO Annual Meeting - Apr 21st, 2026 8:40 am
Why Is Black Diamond (BDTX) Up 19.3% Since Last Earnings Report? - Apr 15th, 2026 9:30 am
BDTX and Brain Metastases: Why CNS Activity Could Matter in 2026 - Apr 9th, 2026 10:21 am
Black Diamond Stock: Weighing Catalysts vs. Concentration - Apr 9th, 2026 10:20 am